Data on the risk of tuberculosis (TB) reactivation with infliximab therapy in patients with inflammatory bowel disease (IBD) who are from countries where TB is particularly prevalent, such as India, remains limited. A recent study sought to evaluate the rate of tubercular reactivation with infliximab in a cohort of patients with IBD.
Data on the risk of tuberculosis (TB) reactivation with infliximab therapy in patients with inflammatory bowel disease (IBD) who are from countries where TB is particularly prevalent, such as India, remains limited. A recent study sought to evaluate the rate of TB reactivation with infliximab in a cohort of patients with IBD (ulcerative colitis [UC] and Crohn disease [CD]).
The study was designed as a retrospective analysis of a database comprising patients with IBD who had previously received at least 1 dose of infliximab. The researchers included 69 patients in the study, of whom 22 had been previously diagnosed with UC and 47 had been diagnosed with CD.
In total, 8 patients developed TB after infliximab therapy. The median duration after the first dose of infliximab to detection of TB was 19 weeks (range, 6-94 weeks). Of these 8 patients, 7 had CD and 1 had UC.
The study’s authors also found that the rate of TB reactivation was higher in patients with CD (14.9% versus 4.5%, P = .21), though the finding was not statistically significant. The rate of TB was also higher among patients with a past history of TB (25% versus 9.8%, respectively). The authors noted that the possibility of the patients who experienced TB recurrence having intestinal TB (and therefore a higher chance of reactivation) was negated by 2 patients already having received anti-tubercular therapy before diagnosis of CD.
In terms of response to infliximab therapy, the authors found that there was no worsening of intestinal symptoms after administration of infliximab, and only 1 patient who developed TB had a primary nonresponse to infliximab.
Though the researchers did note that the study was limited due to a smaller sample size, they were also able to identify clinically significant results which demonstrated that physicians should be cautious before administering anti—tumor necrosis factor (anti-TNF) therapy, as there is a high rate of TB with infliximab in Indian patients with IBD. The authors also stated that the current screening methods could be more effective, and further research should look to identify methods that more accurately predict TB after infliximab therapy.
Reference
Agarwal A, Kedia S, Jain S, et al. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intest Res. 2018; 16(4): 588-598. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223459/?rel=0" ?rel=0" . Published October 2018. Accessed December 20, 2018.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.